Felidale 2.5 mg Coated Tablets for Cats

Main information

  • Trade name:
  • Felidale 2,5 mg
  • Pharmaceutical form:
  • Coated tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Felidale 2,5 mg
    Germany
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • thiamazole
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0415/001
  • Authorization date:
  • 22-02-2012
  • EU code:
  • UK/V/0415/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2012

AN:00442/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Felidale2.5mgCoatedTabletsforCats

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachtabletcontains:

Activesubstance:

Thiamazole 2.5mg

Excipients:

TitaniumDioxide(E171) 1.12mg

Erythrosine(E127) 0.01mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Coatedtablet.

Pinksugar-coatedbiconvextablets,5.5mmdiameter.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cats.

4.2 Indicationsforuse,specifyingthetargetspecies

Forthestabilisationofhyperthyroidismincatspriortosurgicalthyroidectomy.

Forthelong-termtreatmentoffelinehyperthyroidism.

4.3 Contraindications

Donotuseincatssufferingfromsystemicdiseasesuchasprimaryliverdisease

ordiabetesmellitus.

Donotuseincatsshowingsignsofautoimmunedisease.

Donotuseinanimalswithdisordersofwhitebloodcells,suchasneutropenia

andlymphopenia.

Donotuseinanimalswithplateletdisordersandcoagulopathies(particularly

thrombocytopenia).

Donotuseincatswithhypersensitivitytothiamazoleortheexcipient,

polyethyleneglycol.

Issued:May2012

AN:00442/2011

Page2of6

Donotuseinpregnantorlactatingfemales.

Pleaserefertosection4.7.

4.4 Specialwarnings

Asthiamazolecancausehaemoconcentration,catsshouldalwayshaveaccess

todrinkingwater.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Ifmorethan10mgperdayisrequiredanimalsshouldbemonitoredparticularly

carefully.

Useoftheproductincatswithrenaldysfunctionshouldbesubjecttocarefulrisk:

benefitassessmentbytheclinician.Duetotheeffectthiamazolecanhaveon

reducingtheglomerularfiltrationrate,theeffectoftherapyonrenalfunction

shouldbemonitoredcloselyasdeteriorationofanunderlyingconditionmay

occur.

Haematologymustbemonitoredduetoriskofleucopeniaorhaemolytic

anaemia.

Anyanimalthatsuddenlyappearsunwellduringtherapy,particularlyiftheyare

febrile,shouldhaveabloodsampletakenforroutinehaematologyand

biochemistry.Neutropenicanimals(neutrophilcounts<2.5x10 9

/l)shouldbe

treatedwithprophylacticbactericidalantibacterialdrugsandsupportivetherapy.

Pleaserefertosection4.9formonitoringinstructions.

Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Washhandsafteruse.

Inthecaseofaccidentalingestion,seekmedicaladviceimmediatelyandshow

thepackageleafletorthelabeltothephysician.

Thiamazolemaycausevomiting,epigastricdistress,headache,fever,arthralgia,

pruritusandpancytopaenia.Treatmentissymptomatic.

Washhandswithsoapandwaterafterhandlinglitterusedbytreatedanimals.

Donoteat,drinkorsmokewhilehandlingthetabletorusedlitter.

Donothandlethisproductifyouareallergictoantithyroidproducts.Ifallergic

symptomsdevelop,suchasaskinrash,swellingoftheface,lipsoreyesor

difficultyinbreathing,youshouldseekmedicalattentionimmediatelyandshow

thepackageleafletorlabeltothedoctor.

Donotbreakorcrushtablets.

Asthiamazoleisasuspectedhumanteratogen,womenofchild-bearingageand

pregnantwomenshouldweargloveswhenhandlinglitteroftreatedcats.

Pregnantwomenshouldweargloveswhenhandlingtheproduct.

4.6 Adversereactions(frequencyandseriousness)

Issued:May2012

AN:00442/2011

Page3of6

Adversereactionshavebeenreportedfollowinglongtermcontrolof

hyperthyroidism.Inmanycases,signsmaybemildandtransitoryandnota

reasonforwithdrawaloftreatment.Themoreseriouseffectsaremainly

reversiblewhenmedicationisstopped.

Adversereactionsareuncommon.Themostcommonclinicalsideeffectsthat

arereportedincludevomiting,inappetance/anorexia,lethargy,severepruritus

andexcoriationsoftheheadandneck,bleedingdiathesisandicterusassociated

withhepatopathy,andhaematologicalabnormalities(eosinophilia,

lymphocytosis,neutropenia,lymphopenia,slightleucopenia,agranulocytosis,

thrombocytopeniaorhaemolyticanaemia).Thesesideeffectsresolvewithin7-45

daysaftercessationofthiamazoletherapy.

Possibleimmunologicalsideeffectsincludeanaemia,withraresideeffects

includingthrombocytopeniaandserumanti-nuclearantibodies,and,veryrarely,

lymphadenopathycanoccur.Treatmentshouldbestoppedimmediatelyand

alternativetherapyconsideredfollowingasuitableperiodforrecovery.

Followinglong-termtreatmentwiththiamazoleinrodents,anincreasedriskof

neoplasiainthethyroidglandhasbeenshowntooccur,butnoevidenceis

availableincats.

4.7 Useduringpregnancy,lactationorlay

Laboratorystudiesinratsandmicehaveshownevidenceofteratogenicand

embryotoxiceffectsofthiamazole.Thesafetyoftheproductwasnotassessedin

pregnantorlactatingcats.Donotuseinpregnantorlactatingfemales.

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Concurrenttreatmentwithphenobarbitalmayreducetheclinicalefficacyof

thiamazole.

Thiamazoleisknowntoreducethehepaticoxidationofbenzimidazolewormers

andmayleadtoincreasesintheirplasmaconcentrationswhengiven

concurrently.

Thiamazoleisimmunomodulatory,thereforethisshouldbetakenintoaccount

whenconsideringvaccinationprogrammes.

4.9 Amountstobeadministeredandadministrationroute

Fororaladministrationonly.

Forthestabilisationoffelinehyperthyroidismpriortosurgicalremovalofthe

thyroidgland,one2.5mgtabletmorningandevening.Thisshouldensure

euthyroidismwithin3weeksinmostcases.

Forlong-termtreatmentofhyperthyroidism,thestartingdoseshouldbe2.5mg

twicedaily.After3weeks,thedoseshouldbetitratedtoeffectaccordingtothe

serumtotalT4.Doseadjustmentsshouldbemadebyincrementsof2.5mg.

Whereverpossible,thetotaldailydoseshouldbedividedintotwoand

administeredmorningandevening.Tabletsshouldnotbesplit.Theaimshould

betoachievethelowestpossibledoserate.

If,forreasonsofcompliance,oncedailydosingwitha5mgtabletispreferable,

thenthisisacceptablealthoughreducedefficacycanbeexpectedcomparedtoa

Issued:May2012

AN:00442/2011

Page4of6

twicedailyregime.The5mgtabletisalsosuitableforcatsrequiringhigherdose

rates.

Ifmorethan10mgperdayisrequiredanimalsshouldbemonitoredparticularly

carefully.Thedoseadministeredmustnotexceed20mg/day.

Forlong-termtreatmentofhyperthyroidismtheanimalshouldbetreatedfor

life.

Haematology,biochemistryandserumtotalT4shouldbeassessedbefore

initiatingtreatmentandafter3weeks,6weeks,10weeks,20weeks,and

thereafterevery3monthsandthedosetitratedasnecessary.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Intolerancestudiesinyounghealthycats,thefollowingdose-relatedclinicalsigns

occurredatdosesofupto30mg/animal/day:anorexia,vomiting,lethargy,

pruritusandhaematologicalandbiochemicalabnormalitiessuchasneutropenia,

lymphopenia,reducedserumpotassiumandphosphoruslevels,increased

magnesiumandcreatininelevelsandtheoccurrenceofanti-nuclearantibodies.

Atadoseof30mg/daysomecatsshowedsignsofhaemolyticanaemiaand

severeclinicaldeterioration.Someofthesesignsmayalsooccurinhyperthyroid

catstreatedatdosesofupto20mgperday.

Excessivedosesinhyperthyroidcatsmayresultinsignsofhypothyroidism.This

ishoweverunlikely,ashypothyroidismisusuallycorrectedbynegativefeedback

mechanisms.PleaserefertoSection4.6Adversereactions.

Ifoverdosageoccurs,stoptreatmentandgivesymptomaticandsupportive

care.

4.11Withdrawalperiods

Notapplicable.

5. PHARMACOLOGICALPARTICULARS

Pharmacotherapeuticgroup:antithyroidpreparations:sulphur-containing

imidazolederivatives.

ATCVetCode:QH03BB02.

5.1 Pharmacodynamicproperties

Thiamazoleactsbyblockingthebiosynthesisofthyroidhormoneinvivo.The

primaryactionistoinhibitbindingofiodidetotheenzymethyroidperoxidase,

therebypreventingthecatalysediodinationofthyroglobulinandT

andT

synthesis.

5.2 Pharmacokineticparticulars

Followingoraldosinginhealthycats,thiamazoleisrapidlyandcompletely

absorbedwithabioavailabilityof>75%.However,thereisaconsiderable

variationbetweenanimals.Eliminationofthedrugfromcatplasmaisrapidwith

ahalflifeof3.5-4.0hours.Peakplasmalevelsoccurapproximately1-2hours

afterdosing.Cmaxisapproximately0.8µg/ml.

Issued:May2012

AN:00442/2011

Page5of6

Inratsthiamazolehasbeenshowntobepoorlyboundtoplasmaprotein(5%);

40%wasboundtoredbloodcells.Themetabolismofthiamazoleincatshas

notbeeninvestigated,however,inratsthiamazoleisrapidlymetabolisedinthe

thyroidgland,withabout64%oftheadministereddosebeingeliminatedinthe

urineandonly7.8%excretedinfaeces.Thisisincontrastwithmanwherethe

liverisimportantforthemetabolicdegradationofthecompound.Thedrug

residencetimeinthethyroidglandisassumedtobelongerthanintheplasma.

Frommanandratsitisknownthatthedrugcancrosstheplacentaand

concentratesinthefoetalthyroidgland.Thereisalsoahighrateoftransferinto

breastmilk.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Tabletcore:

Lactosemonohydrate

Povidone

Sodiumstarchglycollate

Magnesiumstearate

Coating:

Sucrose

Povidone

Erythrosine

Macrogol

Purifiedtalc

Whitebeeswax

Carnaubawax

Shellac

Titaniumdioxide(E171)

Sodiummethylparahydroxybenzoate(E219)

6.2 Incompatibilities

Notapplicable

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:3years.

6.4 Specialprecautionsforstorage

Donotstoreabove25ºC.

Keepthecontainertightlyclosedinordertoprotectfrommoisture.

Keepthecontainerintheoutercarton.

Issued:May2012

AN:00442/2011

Page6of6

6.5 Natureandcontentsofimmediatepackaging

Whitepolypropylenetubwithwhitelowdensitypolyethylenetamperevidentlid

containing100tablets.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

DechraLimited

DechraHouse

JamageIndustrialEstate

TalkePits

Stoke-on-Trent

Staffordshire

ST71XW

UK

8. MARKETINGAUTHORISATIONNUMBERS

Vm10434/4075

9. DATEOFFIRSTAUTHORISATION

1May2012

10. DATEOFANYREVISIONOFTHETEXT

May2012

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

There are no news related to this product.